Social Enterprise set up by group of philanthropic funds led by George Soros’ Economic Development Fund, with support from Bill & Melinda Gates Foundation.
Babson Diagnostics Raises $31 Million in Series B Funding to Drive Retailization of Customer-First, Convenient, and Highly Accessible Diagnostic Blood Testing
The Series B fundraise will accelerate the commercialization of Babson’s disruptive technology that will make routine blood testing easier, more accessible, and less invasive.
Equifund is one of the highest-grossing platforms in the industry on a per offering basis. In the past 18 months it has launched six Reg-CF offerings and generated over $4 million in investor commitments.
Proceeds from this financing will advance Kineta's lead anti VISTA antibody, KVA12.1 to an IND with the US FDA in 2022.
Pulmocide Raises $92 million in a Series C Financing: Financing to Fund Registration Program for PC945
“We strongly believe in the combination of Pulmocide’s first-in-class science, the robust commercialization strategy for PC945 and the experienced management team that hold a successful track record in this field,” said Sabine Dandiguian, Managing Partner at Jeito Capital.
Novo Holdings Leads US$200M Series A investment in Asia-Based Life Sciences Tools Company Esco Lifesciences Group
Esco Lifesciences Group provides enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. Headquartered in Singapore, Esco has an extensive sales network in over 100 countries, direct sales and service offices in over 20 countries, 8 manufacturing and R&D hubs in the US, Europe, the UK, China, Singapore, Indonesia, and over 1600 employees worldwide.
Akili Interactive Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
The $110M Series D equity financing was led by Neuberger Berman Funds and joined by new investors Polaris Partners; Mirae Assets; Shionogi & Co., Ltd., New Leaf Venture Partners; Dave Baszucki, Founder and CEO of Roblox Corporation; QUAD Investment Management, and Ladera Venture Partners. Existing Akili investors Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, and M Ventures (the corporate VC fund of Merck KGaA, Darmstadt, Germany) all participated in the financing round.
PureTech Health Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
The Series D brings Akili’s total equity funding to $230 million to date and further positions Akili to continue leading the industry in bringing digital therapeutics to patients.
Advances two clinical programs through topline data across four indications. Progresses two preclinical programs to potential lead candidate selection. Brings total funding since inception to $140 million
Evofem intends to use the net proceeds from this offering for the continuation of full commercialization activities related to Phexxi® (lactic acid, citric acid and potassium bitartrate).
Series B financing, led by SPARX Group with participation from Sysmex Corporation and Sumitomo Mitsui Trust Investment as well as existing investors, SBI Group and Itochu Technology Ventures.
FACIT, a commercialization venture firm focused on advancing Ontario's top-tier oncology innovations, announced a new follow-on investment in start-up Nanology Labs ("Nanology"). FACIT led the $3M seed round, alongside co-investors Creative Destruction Lab Angels, Ontario Brain Institute, Ontario Centre of...